Adia Nutrition Inc. (OTC: ADIA) Gets FDA Registration for its Subsidiary Adia Vita

Healthcare innovation continues to be a highly sought-after space among investors, and one of the companies from the space that could be tracked today is Adia Nutrition Inc. (OTC: ADIA). The company was in significant focus yesterday after it made an announcement with regards to a major milestone hit by its subsidiary unit, Adia Labs LLC.

FDA Registration for Adia Labs

In the news release yesterday, the company announced that the registration of Adia Vita from Adia Labs had been accepted by the United States Food and Drug Administration. The company also stated that the acceptance was also a reflection of the notification to the FDA by Adia Labs about the fact that it would store and distribute Adia Vita to clinics and doctors across the United States.

Distribution and Growth

Adia Vita is its high-end stem cell product, and the distribution would give clinics as well as doctors access to high-quality regenerative medicine. It would also help in boosting the company’s revenues significantly. Hence, the company stated that the registration of the product was a ‘game-changing’ development and helped distribute the product to a massive network.

Management Quote

“Registering Adia Vita with the FDA marks a game-changing moment for us,” said Larry Powalisz, CEO of ADIA Nutrition. “We’re deeply grateful to the FDA for their timely and cooperative efforts in making this registration possible so quickly. This milestone allows us to reach a vast network of doctors and clinics across the country, offering a high-quality, cost-effective solution that accelerates client growth. We’re excited to lead the charge in making advanced patient care more affordable and widespread.” Powalisz added, “As of this moment, we are open for business on this front, and we invite any and all medical professionals across the U.S. to give us a call at 321-788-0850 to explore how Adia Vita can enhance their practice.”